<DOC>
	<DOCNO>NCT00687999</DOCNO>
	<brief_summary>The influence insulin sensitivity glucose tolerance effect antiviral therapy HCV remain unclear . The aim present study ( 1 ) To elucidate clinical virological factor associate sustained viral response patient combination therapy PEG-IFN ribavirin . ( 2 ) To clarify influence diabetes mellitus ( DM ) , impair glucose tolerance test ( IGT ) insulin resistance ( IR ) HCV response combination therapy PEG-IFN ribavirin . ( 3 ) To test influence combination therapy HOMA IR</brief_summary>
	<brief_title>NIDDM IR Combination Therapy CHC</brief_title>
	<detailed_description>Total 300 treatment-na√Øve chronic hepatitis C patient enrol . The prevalence NIDDM , IGT IR explore hospital-based study among clinically define chronic hepatitis C Taiwanese . The clinical manifestation chronic hepatitis C biochemical , virological histopathological aspect evaluate . Liver enzymes measure multichannel autoanalyzer . Virological marker HCV include serum HCV RNA detect use standardize automated qualitative PCR assay , HCV RNA genotype determine genotype 1a , 1b , 2a , 2b 3a serum HCV RNA level measure use branch DNA assay . The liver histology assess score disease activity grade quantitatively accord histological activity index ( HAI ) . Patients assign diagnosis DM document use oral hypoglycemic medication insulin , random glucose excess 200 mg/dL , fast glucose great 126 mg/dL two occasion . A standard oral glucose tolerance test ( OGTT ) perform . In addition OGTT , history diabetes mellitus chart review and/or questionnaire also obtain . Standard antiviral therapy carry PEG-IFN , give subcutaneously weekly plus 1,000-1,200 mg oral ribavirin daily . Patients receive another 24 week follow-up period determine virological response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Chronic hepatitis C patient positive antiHCV 6 month HCV RNA 2 . No overt hepatic failure decompensated liver cirrhosis ( ChildPugh class B C ) hepatocellular carcinoma . 1 . Positive hepatitis B surface antigen ( HBsAg ) concomitant human immunodeficiency virus infection 2 . With type hepatitis include autoimmune hepatitis , primary biliary cirrhosis , sclerosing cholangitis , Wilson 's disease , alpha 1antitrypsin deficiency 3 . Current past history alcohol abuse ( 80 mL ethanol per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>diabetes</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>combination therapy</keyword>
</DOC>